Subscribe

Clinical Trials

Last updated on 
Clinical Trials
@hayleymurrayphoto via Unsplash

Ovarian Cancer

Pubmed Link: Clinical Trials Published in the last two years

Paperpile Link: List of articles ready to import into Paperpile

List of articles

  1. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study Florence Joly, Michel Fabbro, Dominique Berton, Magali Provansal Gross, Pierre-Emmanuel Brachet et al.Sep 2022Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Ovarian EpithelialFemaleHumansIndazolesNeoplasm Recurrence, LocalOvarian NeoplasmsPaclitaxelPyrimidinesSulfonamidesAbstract FullText Related▿ Save▿
  2. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical TrialTiantian Wang, Jie Tang, Hongying Yang, Ning Li, Lingying Wu et al.Aug 2022AdultAgedAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialDoxorubicinFemaleHumansMiddle AgedOvarian NeoplasmsPolyethylene GlycolsPyridinesVascular Endothelial Growth Factor AYoung AdultAbstract FullText Related▿ Save▿
  3. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial Andrew R Clamp, Elizabeth C James, Iain A McNeish, Richard Kaplan, Jonathan A Ledermann et al.Jul 2022Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Ovarian EpithelialFallopian TubesFemaleHumansMiddle AgedOvarian NeoplasmsPaclitaxelAbstract FullText Related▿ Save▿
  4. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Sandra Goble, Amit M Oza et al.Apr 2022AdolescentBRCA1 ProteinBRCA2 ProteinHumansIndolesMiddle AgedMutationOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsProspective StudiesAbstract FullText Related▿ Save▿
  5. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical TrialMyong Cheol Lim, Suk-Joon Chang, Boram Park, Sang-Yoon Park, HIPEC for Ovarian Cancer Collaborators et al.May 2022Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyMiddle AgedOvarian NeoplasmsSingle-Blind MethodAbstract FullText Related▿ Save▿
  6. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer Adriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, Toon Van Gorp, Ignace Vergote et al.Apr 2022Antineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Ovarian EpithelialDoxorubicinFemaleHumansNeoplasm Recurrence, LocalOvarian NeoplasmsPhthalazinesPhysiciansPiperazinesPolyethylene GlycolsAbstract FullText Related▿ Save▿
  7. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancerNicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici, Elena Biagioli, BAROCCO study group et al.Mar 2022Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialFemaleHumansNeoplasm Recurrence, LocalOvarian NeoplasmsPaclitaxelPeripheral Nervous System DiseasesPhthalazinesPiperazinesQuinazolinesAbstract FullText Related▿ Save▿
  8. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, Andreas du Bois, DESKTOP III Investigators et al.Dec 2021AgedAntineoplastic AgentsCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProportional Hazards ModelsQuality of LifeSurvival AnalysisAbstract FullText Related▿ Save▿
  9. Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGONS Cianci, C Fedele, G Vizzielli, A Fagotti, G Scambia et al.Feb 2022AdultAgedCarcinoma, Ovarian EpithelialChest TubesCytoreduction Surgical ProceduresDiaphragmFemaleHumansIntraoperative CareLogistic ModelsMiddle AgedOvarian NeoplasmsPleural EffusionPostoperative ComplicationsThoracostomyAbstract FullText Related▿ Save▿
  10. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, Elizabeth S Lowe, Paul DiSilvestro et al.Dec 2021AdolescentAdultAgedAged, 80 and overBRCA1 ProteinBRCA2 ProteinCystadenocarcinoma, SerousDouble-Blind MethodEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMaintenance ChemotherapyMiddle AgedMutationOvarian NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPrognosisSurvival RateYoung AdultAbstract FullText Related▿ Save▿
  11. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)Olivier Trédan, Magali Provansal, Cyril Abdeddaim, Fabien Brocard, Isabelle Ray-Coquard et al.Jan 2022AdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPhenylurea CompoundsPlatinumPyridinesResponse Evaluation Criteria in Solid TumorsTamoxifenTreatment OutcomeAbstract FullText Related▿ Save▿
  12. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer G E Konecny, A E Wahner Hendrickson, T M Davidson, P Haluska, D J Slamon et al.Dec 2021Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCarcinoma, Ovarian EpithelialFemaleHumansInsulin-Like Growth Factor Binding Protein 2Middle AgedNeoplasm StagingOvarian NeoplasmsPaclitaxelProgression-Free SurvivalSomatomedinsAbstract FullText Related▿ Save▿
  13. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancerBradley J Monk, Robert L Coleman, Keiichi Fujiwara, Iain A McNeish, Rebecca S Kristeleit et al.Dec 2021Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialDouble-Blind MethodFemaleHumansIndolesMaintenance ChemotherapyNivolumabOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAbstract FullText Related▿ Save▿
  14. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, Patricia Pautier, Domenica Lorusso et al.Nov 2021AdultAgedAged, 80 and overCarbolinesDoxorubicinDrug Resistance, NeoplasmFemaleHeterocyclic Compounds, 4 or More RingsHumansInfusions, IntravenousMiddle AgedOvarian NeoplasmsPolyethylene GlycolsProgression-Free SurvivalTopotecanAbstract FullText Related▿ Save▿
  15. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial Bradley J Monk, Nicoletta Colombo, Amit M Oza, Carlos Linn, Jonathan A Ledermann et al.Sep 2021AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Ovarian EpithelialDrug-Related Side Effects and Adverse ReactionsFemaleHumansImmune Checkpoint InhibitorsMaintenance ChemotherapyMiddle AgedOvarian NeoplasmsProgression-Free SurvivalAbstract FullText Related▿ Save▿

Endometrial Cancer

Pubmed link: Clinical Trials published in the last four years

List of articles

  1. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyMaria M Rubinstein, Eric Rios Doria, Jason Konner, Dmitriy Zamarin, Vicky Makker et al.Feb 2023FemaleHumansImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalEndometrial NeoplasmsAbstract FullText Related▿ Save▿
  2. A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgeryKatherine Tucker, Stephanie Sullivan, Allison M Deal, Sean D McCabe, Paola A Gehrig et al.Sep 2022AgedCounselingEndometrial NeoplasmsFemaleHumansInformed ConsentMiddle AgedMultimediaPatient SatisfactionProspective StudiesSurveys and QuestionnairesAbstract FullText Related▿ Save▿
  3. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, Michel Fabbro, Isabelle Ray-Coquard et al.Jul 2022AgedAnastrozoleAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBreast NeoplasmsEndometrial NeoplasmsFemaleHumansMTOR InhibitorsMorpholinesPhosphatidylinositol 3-KinasesPyrimidinesTOR Serine-Threonine KinasesAbstract FullText Related▿ Save▿
  4. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, David S Miller, Robert L Coleman et al.Mar 2022Antineoplastic Combined Chemotherapy ProtocolsDrug CombinationsEndometrial NeoplasmsEstradiolEstriolEstroneEverolimusFemaleHumansLetrozoleNeoplasm Recurrence, LocalPhosphatidylinositol 3-KinasesAbstract FullText Related▿ Save▿
  5. Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerVicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Domenica Lorusso, Study 309–KEYNOTE-775 Investigators et al.Feb 2022AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsFemaleHumansMiddle AgedPhenylurea CompoundsQuinolinesSurvival AnalysisAbstract FullText Related▿ Save▿
  6. Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trialAbigail S Zamorano, Elise M Wilson, Jingxia Liu, Graham A Colditz, Andrea R Hagemann et al.Sep 2021AdultAgedAged, 80 and overBody Mass IndexCancer SurvivorsEndometrial NeoplasmsExerciseFemaleHumansMiddle AgedObesityProspective StudiesQuality of LifeSurveys and QuestionnairesText MessagingAbstract FullText Related▿ Save▿
  7. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trialMonika Janda, Kristy P Robledo, Val Gebski, Amanda Tristram, Andreas Obermair et al.Apr 2021Endometrial NeoplasmsFemaleHumansIntrauterine Devices, MedicatedLevonorgestrelMetforminMiddle AgedNeoplasm StagingWeight LossWeight Reduction ProgramsAbstract FullText Related▿ Save▿
  8. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancerBrian M Slomovitz, Anca Chelariu-Raicu, Kathleen M Schmeler, Judith Wolf, Robert L Coleman et al.Nov 2020AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCetuximabEndometrial NeoplasmsErbB ReceptorsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalAbstract FullText Related▿ Save▿
  9. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, Peter E Schwartz, Alessandro D Santin et al.Aug 2020AgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabAbstract FullText Related▿ Save▿
  10. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trialD Lorusso, G Ferrandina, N Colombo, G Maltese, G Scambia et al.Dec 2019AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinEndometrial NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPaclitaxelProgression-Free SurvivalProspective StudiesAbstract FullText Related▿ Save▿
  11. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, Carien L Creutzberg, PORTEC Study Group et al.Sep 2019AgedCarboplatinChemoradiotherapy, AdjuvantCisplatinDisease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsEndometrial NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPaclitaxelRadiotherapyRisk FactorsTreatment OutcomeAbstract FullText Related▿ Save▿
  12. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignmentRoy Kessous, Jeffrey How, Jeremie Abitbol, Walter H Gotlieb, Susie Lau et al.Sep 2019AgedColoring AgentsEndometrial NeoplasmsFemaleHumansIndocyanine GreenLymphatic MetastasisMiddle AgedProspective StudiesRosaniline DyesSentinel Lymph NodeSentinel Lymph Node BiopsyTechnetiumAbstract FullText Related▿ Save▿
  13. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial CancerDaniela Matei, Virginia Filiaci, Marcus E Randall, Helen Q Huang, David S Miller et al.Jun 2019AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPrognosisQuality of LifeRecurrenceStatistics, NonparametricTreatment OutcomeAbstract FullText Related▿ Save▿

Cervical Cancer

Pubmed link: Cervical Cancer Trials in the last three years

ReadcubeLists
Readcube format - Can be downloaded for any reference manager

Vulvar Cancer

Coming Soon

Surgical Trials

Coming Soon